We investigated the efficiency of activated polyamidoamine maximal after transfection with 18:1 (w/w) activated dendrimers, a new class of nonviral vectors, to transfect dendrimer:plasmid DNA ratio and culture for 3 days. The rabbit and human corneas in ex vivo culture. In addition to supernatant of corneas transfected with TNFR-Ig plasmid assessing the expression of a marker gene we have demcontained TNFR-Ig protein which was able to inhibit TNFonstrated that this approach can be used to induce the promediated cytotoxicity in a bioassay. We have therefore duction of TNF receptor fusion protein (TNFR-Ig), a protein shown that activated dendrimers are an efficient nonviral with therapeutic potential. Whole thickness rabbit or human vector capable of transducing corneal endothelial cells ex corneas were transfected ex vivo with complexes convivo. They may have applications in gene-based sisting of dendrimers and plasmids containing lacZ or approaches aimed at prevention of corneal allograft TNFR-Ig genes. Following optimisation 6-10% of the correjection or in treatment of other disorders of corneal neal endothelial cells expressed the marker gene.
Polyamidoamine dendrimers are a new class of efficient nonviral vectors for gene transfer [1] [2] [3] [4] to cell lines and organs. 5 They are synthetic spherical macromolecules with branches radiating from a central core ( Figure 1 ). They terminate at charged and uncharged amino groups and bind to the negatively charged DNA to form a complex. 3, 4 Dendrimer-DNA complexes possessing net positive charges bind to negatively charged receptors such as sialyated glycoproteins on the surface of eukaryotic cells. Following internalisation, the dendrimers buffer the endosomes, thus inhibiting pH-dependent lysosomal nucleases. This ensures stability of the complexes and allows the transport of intact DNA to the nucleus. Transfection efficiency of polyamidoamine dendrimers can be increased more than 50-fold by heat treatment of the intact dendrimers in solvents such as water or butanol. Some branches of the molecule are trimmed away during this process resulting in a more flexible molecule, termed an activated dendrimer, without interfering with its size or shape. 6 One feature of dendrimers is low cytotoxicity in vitro and in vivo, 7 and non-activated dendrimers have been shown to be efficient at mediating gene delivery of viral interleukin-10 in a murine cardiac allotransplant model. 5 The corneal endothelium is a cell monolayer on the inner surface of the cornea and is critical in the maintenance of corneal transparency and normal visual acuity. It is of neural crest origin and, in the adult human, virtually non-replicative. 8 Death or damage of the endothelial cells results in opacification of the cornea and blindness. Failure of corneal endothelial function is the commonest indication for transplantation of the corneathe most frequently transplanted allogeneic tissue with around 40 000 grafts performed annually in the USA alone. 9 The cornea is easily accessible, and, because of its transparency, all the effects of gene transfer can be easily monitored. While corneal transplantation is generally successful, there is a significant failure rate of 26% over 5 years 10 mainly due to endothelial graft rejection. We have therefore investigated the potential of gene-based approaches to modulate the immune response against the corneal allograft. We have studied adenoviral vectors 11, 12 for gene transfer and shown that they are highly efficient. However, their immunogenicity is likely to prove problematic, especially in the transplant setting. We have therefore examined the potential of activated dendrimers as nonviral vectors for gene transfer to this tissue. To date, these have been described only as gene transfer vectors for cell lines. 1, 6 In this article we extend the findings to corneal ex vivo culture.
Whole thickness quarter corneas were incubated for 3 h in a 96-well plate with dendrimer-DNA complexes which consist of plasmid DNA encoding for the marker enzyme ␤-galactosidase, and activated dendrimers. After 3 days incubation in medium the samples were stained with X-gal. Six to 10% of endothelial cells in rabbit cornea stained blue (Figure 2a ), indicating expression of the marker gene (cell density is approximately 2500/mm 2 ). Similar data were seen with human corneas (Figure 2b ), although transfection efficiency was lower. No expression was seen in the epithelial or stromal layers of the cornea, as we have previously reported using adenoviral vectors. 11, 12 No expression of ␤-galactosidase was seen in corneas incubated with plasmid DNA or with dendrimers alone (data not shown).
The transfection efficiency of the dendrimer-DNA complex depends on its overall electrostatic charge. Highest levels of marker gene expression were obtained with 36 g of dendrimers mixed with 2 g of plasmid DNA per quarter rabbit cornea on day 3 of incubation (18:1 w/w ratio; Figure 3a ). Low efficiency was achieved with ratios below 14:1, whereas above 18:1 efficiency remains high.
In order to determine the optimal amount of DNA for transfection, dendrimers were complexed with 0.5-8 g of pCMV-␤ at a 18:1 ratio and incubated for 3 days. Highest numbers of transfected cells were observed when 2 g of DNA per quarter cornea was used (Figure 3b ), although significant levels of gene expression were seen with 0.5 g. The efficiency dropped considerably when more than 4 g of DNA was used, probably due to toxicity of the complex. For all subsequent experiments 2 g of plasmid DNA was used at a 18:1 dendrimer: DNA ratio.
Because of the limited availability of human corneas for research purposes we optimised transfection conditions with rabbit corneas which are similar to human in size and structure. As discussed above, under optimised conditions 6-10% of the rabbit corneal endothelial cells expressed ␤-galactosidase. This was reproducible with more than 20 quarter rabbit corneas transfected under optimised conditions. Using two human corneas 53 ± 19 (mean ± standard deviation) cells per microscopic field (about 2%) expressed ␤-galactosidase. Optimal conditions may vary slightly between species so that a higher efficiency in human corneas might be possible. As in the rabbit, no expression was seen in corneal epithelium or stroma.
Rabbit quarter corneas were incubated for 1, 3 21 and 28 days after initial 3 h transfection and processed either for histochemistry or for a colorimetric assay. Untransfected samples were used as negative controls for each time-point. Up to 250 or about 10% of endothelial cells per microscopic field expressed detectable levels of ␤-galactosidase after 3 days (Figure 4a ). Numbers dropped thereafter but some positive cells were detected even after 28 days. The colorimetric assay for ␤-galactosidase activity revealed a similar peak at 3 days with a mean of 115 U per quarter rabbit cornea. After 14 days no significant expression could be detected (Figure 4b ). Tumour necrosis factor (TNF) is present at high levels during corneal allograft rejection in a rabbit model and blocking the action of TNF with soluble TNF receptor immunoglobulin (TNFR-Ig), a fusion protein consisting of p55 TNF receptor and the Fc segment of human IgG, can lead to prolongation in survival of some grafts. 13 Delivery of genes encoding similar constructs has been 
-galactosidase was quantified by counting transfected cells (a), as described in the legend to Figure 3, and by a colorimetric assay (b). O-nitrophenyl-␤-d-galactopyranoside was used as a substrate for the ␤-galactosidase in cell lysates. Corneal specimens were washed five times with PBS and lysed with 90 l Tris-HCL (250 mm, pH 8.0) by three freeze-thaw cycles to release cytoplasmic contents. Tissue debris was removed by centrifugation at 14 000 g in a microcentrifuge at 4°C, for 10 min. Absorbance was measured at 414 nm in a microtitre plate reader (Titretek multiscan MCC/340; Labsystems, Joensuu, Finland). The results represent the mean of at least three quarter corneas ± standard deviation.
shown to be efficient in a rat model in preventing autoimmune encephalitis [14] [15] [16] and in reducing eye damage in experimental autoimmune uveoretinitis. 17, 18 We therefore examined the ability of dendrimers to deliver the gene encoding TNFR-Ig to corneal endothelium. Following transfection with the dendrimer-DNA complex of three quarter rabbit corneas, supernatant was collected at day 1 and every second day thereafter until day 9. Expression of TNFR-Ig was measured by a sandwich ELISA 19 detecting the Fc segment of human IgG. No TNFR-Ig was detected in supernatant from untransfected corneas (data not shown). The amount of secreted TNFR-Ig was maximal in the early part of the time-course, however, the protein continued to be secreted on day 9, although at a decreased rate, with the total amount of TNFR-Ig produced per quarter cornea exceeding 9 ng at this time (Figure 5a ). The biological activity of the TNFR-Ig was measured by blocking the cytotoxic effect of added TNF in a bioassay 19 in which its ability to protect L929 cells from TNF induced cell death was assessed (Figure 5b) . A peak concentration of bioactive TNFR-Ig was reached at day 3. The concentration remained higher than background determined by an untransfected corneal sample until day 9. The amount of TNFR-Ig needed to block TNF activity in vivo is not known, as it will be dependent on factors such as aqueous humour turnover. However, the amount of TNF used in the bioassay was within the range found during allograft rejection. 13 Gene therapy has potential in the prevention of corneal graft rejection and in the treatment of corneal dystrophies and various types of endothelial degeneration such as after trauma or intraocular surgery. However, its applicability is limited by the immunogenicity of viral vectors used to transfer the genes. In order to overcome this we have previously investigated the use of liposomes and lipoadenofection 20 as well as peptide targeted gene delivery 21 to transfer genes to the cornea. In our hands, lipo- somes on their own are inefficient vectors ex vivo, 20 although others have reported low ␤-galactosidase expression following injection of the liposome-DNA complexes directly into the anterior chamber of rats. 22 We and others have found that peptide-mediated gene delivery 21, 23 and lipoadenofection 20 show a similar transfection efficiency to that reported here. However, the efficiency of these three approaches have yet to be directly compared. The nonviral strategies lead to transient expression of the marker gene. Activated dendrimers differ from peptide-mediated gene delivery and lipoadenofection in that the vector consists of a single component (which must be mixed with the plasmid DNA) rather than a combination of liposomes and either peptide or virus. This would be likely to simplify its clinical application.
Figure 5 Expression of TNFR-Ig. Rabbit corneas were transfected with activated dendrimer-DNA complexes encoding TNFR-Ig using the conditions described in Figures 2 and 4. The levels of TNFR-Ig in the supernatant were determined by ELISA (a) and are shown as the cumulative total TNFRIg expressed per quarter cornea (mean of three samples). The plasmid encoding TNFR-Ig was made by PCR amplification of the extracellular domain
In addition to the delivery of plasmids encoding a marker gene, we have also demonstrated that activated dendrimers can be used to deliver a plasmid encoding TNFR-Ig. We have previously shown that high levels of TNF are present in aqueous humour from corneal allografts undergoing rejection, but not from autografts or normal eyes, indicating a possible functional role of this cytokine in pathogenesis of rejection. 13 Furthermore, administration of TNFR-Ig protein intracamerally (injection directly into the anterior chamber of the eye) prolonged graft survival in three of seven animals. 13 We have shown that corneas transduced with TNFR-Ig gene ex vivo continue to express the protein for more than 9 days, although at diminishing amounts. This expressed protein is active and can block the action of TNF. Genebased approaches to prevention or reversal of graft rejection, using TNFR-Ig, may therefore have clinical significance.
A characteristic feature of dendrimers is their relatively low toxicity in vitro 6 and in vivo. 7 Although viral vectors are more efficient, their use in vivo is limited by immunogenicity and safety considerations. In comparison, dendrimers and peptide-mediated gene delivery are likely to prove considerably less immunogenic. Lipoadenofection, while showing a reduced immunogenicity when compared with adenoviral gene delivery, is likely to be somewhat immunogenic owing to its viral component. Furthermore, serum and antibiotics do not interfere with transfection efficiency of activated dendrimers so that cells and tissues do not need do be deprived of any important component of their culture medium. In the case of the cornea this allows serum to be present during the transfection, thus reducing cell death. This is particularly important as the corneal endothelial cells are arrested in the G1 phase of the cell cycle and are essentially incapable of replication. 8 Thus damage to the endothelium is irreversible, and must be minimised.
In summary, activated dendrimers are a promising nonviral vector for experimental research and possibly clinical application. Following optimisation, the transfection is easy and rapid to perform. In the clinical context this system could be readily applied at the time of ex vivo corneal storage before transplantation.
